Antithyroid drugs

Table   Graphic     exposition period:

Congenital malformations
Adverse outcome PastilleOR 95%CII2k No. casesNo. exposedpublication biasROB???
All congenital malformations (majors, minors, majors and minors, or unspecified)harm, strong evidence1.24 [1.10, 1.40]21%12 studies250,10819,467low NApptx
Major congenital malformationsinsufficient precision1.32 [0.95, 1.83]0%6 studies1973,475serious NApptx
Urinary malformationsharm, weak evidence1.69 [1.10, 2.61]58%3 studies17,72915,800not evaluable NApptx
Genital anomaliesinsufficient precision1.17 [0.96, 1.41]0%3 studies25,84815,800not evaluable NApptx
Respiratory system anomaliesinsufficient precision1.16 [0.67, 2.01]71%3 studies16,03715,800not evaluable NApptx
Congenital heart defectsinsufficient precision1.33 [0.98, 1.79]71%3 studies77,71315,800not evaluable NApptx
Ear, face and neck anomaliesinsufficient precision1.50 [0.59, 3.82]0%2 studies9172,909not evaluable NApptx
Eye defectsinsufficient precision1.39 [0.70, 2.74]0%2 studies2,4932,909not evaluable NApptx
Limb defectsinsufficient precision1.08 [0.82, 1.41]61%3 studies74,80015,800not evaluable NApptx
Severe congenital heart defectinsufficient precision0.63 [0.04, 9.47]71%2 studies7392,757not evaluable NApptx
Abdominal wall defectsharm, strong evidence3.37 [1.63, 6.96]0%2 studies9332,909not evaluable NApptx
Cardiac septal defectssignal1.87 [1.14, 3.06]-1 study1,097not evaluable NApptx
Craniosynostosisinsufficient precision1.53 [0.43, 5.51]0%3 studies1,5372,684not evaluable NApptx
Digestive system anomaliesharm, strong evidence1.36 [1.08, 1.71]0%2 studies12,07013,337not evaluable NApptx
Nervous system anomaliesharm, strong evidence1.45 [1.06, 2.00]0%2 studies5,88413,337not evaluable NApptx
Syndromes and chromosomal abnormalitiesinsufficient precision0.88 [0.34, 2.27]26%2 studies5,5572,909not evaluable NApptx
Ano-rectal atresia and stenosisinsufficient precision2.04 [0.36, 11.46]53%2 studies1,0562,644not evaluable NApptx
Aortic valve atresia/stenosisinsufficient precision1.75 [0.07, 44.39]71%2 studies4942,643not evaluable NApptx
Carbimazole embryopathyinsufficient precision5.24 [0.80, 34.53]50%2 studies2,04813,095not evaluable NApptx
Choanal atresiaharm, strong evidence12.25 [5.02, 29.88]0%2 studies119139not evaluable NApptx
Omphaloceleharm, strong evidence6.20 [2.78, 13.83]0%2 studies1602,757not evaluable NApptx
Situs inversusharm, strong evidence16.80 [2.99, 94.32]35%2 studies272,757not evaluable NApptx
Coarctation of aortasignal3.99 [1.02, 15.54]-1 study1,13714not evaluable NApptx
32 non statistically significant endpoints reported in only one study

Growth parameters and prematurity
Adverse outcome PastilleOR 95%CII2k No. casesNo. exposedpublication biasROB???
Preterm (< 37 weeks)no evidence of harm0.95 [0.78, 1.16]3%11 studies6392,427low NApptx
Low birth weight (< 2500g)insufficient precision1.34 [0.78, 2.32]55%4 studies3071,324not evaluable NApptx
Small for gestational age (weight)insufficient precision1.06 [0.86, 1.30]0%3 studies5601,400not evaluable NApptx
Small for gestational age (length)no data--0 studypptx
Small head circumference for gestational ageno data--0 studypptx
2 non statistically significant endpoints reported in only one study

Maternal consequences
Adverse outcome PastilleOR 95%CII2k No. casesNo. exposedpublication biasROB???
Maternal liver disorder / failure during pregnancyno data--0 studypptx
Preeclampsiainsufficient precision1.13 [0.13, 10.01]0%2 studies4310not evaluable NApptx
2 non statistically significant endpoints reported in only one study

Neonatal disorders
Adverse outcome PastilleOR 95%CII2k No. casesNo. exposedpublication biasROB???
Goiterno data2.03 [0.18, 23.21]57%3 studies27170not evaluable NApptx
Hypothyroidism (fetal/neonatal)insufficient precision2.54 [0.51, 12.61]6%4 studies11346not evaluable NApptx
Hyperthyroidism / Thyrotoxicosis (fetal/neonatal)no data3.27 [0.40, 26.43]40%3 studies15204not evaluable NApptx
Neonatal hyperthyrotropinemiasignal3.02 [1.04, 8.78]-1 study18111not evaluable NApptx
Neonatal deathno data--0 studypptx
3 non statistically significant endpoints reported in only one study

Intrauterine deaths
Adverse outcome PastilleOR 95%CII2k No. casesNo. exposedpublication biasROB???
Early intrauterine death (< 22 weeks)insufficient precision1.89 [0.68, 5.24]85%4 studies5803,399not evaluable NApptx
Intrauterine deaths (as a whole)insufficient precision1.41 [0.88, 2.25]0%5 studies86435not evaluable NApptx
Elective termination of pregnancyharm, strong evidence1.97 [1.17, 3.33]0%3 studies993,295not evaluable NApptx
Late intrauterine deaths (> 22 weeks)no data0.20 [0.01, 6.47]74%2 studies9167not evaluable NApptx
Perinatal deathinsufficient precision0.76 [0.36, 1.56]0%3 studies293,350not evaluable NApptx
Ectopic pregnancyno data--0 studypptx

Neuro-developmental disorders
Adverse outcome PastilleOR 95%CII2k No. casesNo. exposedpublication biasROB???
Neuro-developmental disorders (as a whole)signal5.34 [2.17, 13.10]-1 study69220not evaluable NApptx